Hormone replacement therapy and surveillance considerations

Maturitas

Volumn 43, Issue SUPPL., 2002, Pages

  Brood van Zanten, Monique M A ^a   Barentsen, Ronald ^a   Van Der Mooren, Marius J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advantages; Hormone replacement therapy; Risk; Surveillance

Indexed keywords

ANAMNESIS; BLEEDING; BREAST CARCINOMA; CANCER RISK; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; COLORECTAL CARCINOMA; DEMENTIA; DIAGNOSTIC PROCEDURE; ENDOMETRIUM CARCINOMA; EUROPE; HORMONE SUBSTITUTION; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; OSTEOPOROSIS; OVARY CARCINOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SATISFACTION; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0037200672     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(02)00149-4     Document Type: Review

References (45)

1. Oldenhave A., Netelenbos C. Pathogenesis of climacteric complaints: Ready for the change. Lancet. 343:1994;649-653.
2. Cobin R.H. AACE medical guidelines for clinical practice for management of menopause. Endocr. Pract. 5:1999;354-366.
3. Harrison-Woolrych M., Purdie D. Breast and pelvic examination in women taking hormone replacement therapy. Br. J. Obstet. Gynaecol. 108:2001;1201-1203.
4. The ESHRE Capri Workshop Group, Crosignani P.G., Rubin B.L. Screening before and during the use of oral contraceptives and hormone replacement therapy. Hum. Reprod. 15:2000;485-492.
5. Kenemans P., van Unnik G.A., Mijatovic V., van der Mooren M.J. Perspectives in hormone replacement therapy. Maturitas. 15:(Suppl. 1):2001;S41-S48.
6. South-Paul J.E. Osteoporosis: part I. Evaluation and assessment. Am. Fam. Phys. 63:2001;897-908.
7. NIH Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consens Statement 2000;17:1-45.
8. Torgerson D.J., Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomised trials. J. Am. Med. Assoc. 285:2001;2909-2910.
9. AACE 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Osteoporosis Task Force, Endocr. Pract. 2001;7:293-312.
10. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280:1998;605-613.
11. Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann. Intern. Med. 135:2001;1-8.
12. Alexander K.P., Newby L.K., Hellkamp A.S., Harrington R.A., Peterson E.D., Kopecky S., Langer A., O'Gara P., O'Connor C.M., Daly R.N., Califf R.M., Khan S., Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J. Am. Coll. Cardiol. 38:2001;1-7.
13. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
14. Grodstein F. Postmenopausal hormone therapy and mortality. New Engl. J. Med. 336:1997;1769-1775.
15. Hu F.B., Stampfer M.J., Manson J.E., Grodstein F., Colditz G.A., Speizer F.E., Willett W.C. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. New Engl. J. Med. 343:2000;530-537.
16. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M., Schenck-Gustafsson K., Smith S.C. Jr, Taubert K.A., Wenger N.K. American Heart Association. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.
17. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomised, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb. Haemost. 84:2000;961-967.
18. Cushman M., Psaty B.M., Meilahn E.N., Dobs A.S., Kuller L.H. Postmenopausal hormone therapy and concentrations of protein C and antithrombin in elderly women. Br. J. Haematol. 114:2001;162-168.
19. Carr BR. Progestogens: effect on water/salt metabolism and blood pressure, In: Consensus Development Conference on Progestogens, Int. Proc. J. 1989;1:87-92.
20. Manson J.E., Martin K.A. Clinical practice. Postmenopausal Hormone-Replacement Therapy. New Engl. J. Med. 345:2001;34-40.
21. Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 1 08 411 women without breast cancer. Lancet. 350:1997;1047-1059.
22. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:2000;485-491.
23. Verheul H.A., Coelingh-Bennink H.J., Kenemans P., Atsma W.J., Burger C.W., Eden J.A., Hammar M., Marsden J., Purdie D.W. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas. 36:2000;1-17.
24. Manjer J., Malina J., Berglund G., Bondeson L., Garne J.P., Janzon L. Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int. J. Cancer. 92:2001;919-922.
25. Colditz G.A., Rosner B.A., Speizer F.E. Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J. Natl. Cancer Inst. 88:1996;365-371.
26. Sellers T.A., Mink P.J., Cerhan J.R., Zheng W., Anderson K.E., Kushi L.H., Folsom A.R. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann. Intern. Med. 127:1997;973-980.
27. O'Meara E.S., Rossing M.A., Daling J.R., Elmore J.G., Barlow W.E., Weiss N.S. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst. 93:2001;733-734.
28. Byrne C., Connolly J.L., Colditz G.A., Schnitt S.J. Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer. 15:2000;2046-2052.
29. Salminen T.M., Saarenmaa I.E., Heikkila M.M., Hakama M. Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy. Acta Oncol. 39:2000;969-972.
30. Rutter C.M., Mandelson M.T., Laya M.B., Taplin S.H. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. J. Am. Med. Assoc. 285:2001;171-176.
31. Marugg R.C., van der Mooren M.J., Hendriks J.H., Rolland R., Ruijs S.H. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur. Radiol. 7:1997;749-755.
32. Sendag F., Cosan Terek M., Ozsener S., Oztekin K., Bilgin O., Bilgen I., Memis A. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil. Steril. 76:2001;445-450.
33. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85:1995;304-313.
34. Archer D.F. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause. 8:2001;245-251.
35. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1997;458-461.
36. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. J. Am. Med. Assoc. 273:1995;199-208.
37. Colacurci N., De Franciscis P., Cobellis L., Nazzaro G., De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas. 35:2000;167-173.
38. Burger C.W., van Leeuwen F.E., Scheele F., Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas. 32:1999;69-76.
39. Kenemans P., van de Weijer P.H.M., Barentsen R., Practical H.R.T. Vaginal bleeding episodes associated with combined HRT. 1996;31-48 Medical Forum International, Zeist, The Netherlands.
40. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Am. Med. Assoc. 285:2001;1460-1465.
41. Hernandez E. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. J. Am. Med. Assoc. 285:2001;3089-3090.
42. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J. Am. Med. Assoc. 282:1999;637-645.
43. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., Rautaharju P., Harper K.D. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: 4-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomised trial. J. Am. Med. Assoc. 287:2002;847-857.
44. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., Jordan V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. 281:1999;2189-2197.
45. Lippman M.E., Krueger K.A., Eckert S., Sashegyi A., Walls E.L., Jamal S., Cauley J.A., Cummings S.R. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J. Clin. Oncol. 19:2001;3111-3116.